Read by QxMD icon Read

Susan Leslie Clinic for Neuroendocrine Tumours

shared collection
23 papers 0 to 25 followers Educational key papers on management of NET.
Simron Singh, Sylvia L Asa, Chris Dey, Hagen Kennecke, David Laidley, Calvin Law, Timothy Asmis, David Chan, Shereen Ezzat, Rachel Goodwin, Ozgur Mete, Janice Pasieka, Juan Rivera, Ralph Wong, Eva Segelov, Daniel Rayson
The majority of neuroendocrine tumors originate in the digestive system and incidence is increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis and clinical management, updated guidance on the diagnosis and treatment of gastrointestinal neuroendocrine tumors (GI-NETs) are of clinical importance. Well-differentiated GI-NETs may exhibit indolent clinical behavior and are often metastatic at diagnosis. Some NET patients will develop secretory disease requiring symptom control to optimize quality of life and clinical outcomes...
June 2016: Cancer Treatment Reviews
G Delle Fave, D O'Toole, A Sundin, B Taal, P Ferolla, J K Ramage, D Ferone, T Ito, W Weber, Z Zheng-Pei, W W De Herder, A Pascher, P Ruszniewski
No abstract text is available yet for this article.
2016: Neuroendocrinology
M Falconi, B Eriksson, G Kaltsas, D K Bartsch, J Capdevila, M Caplin, B Kos-Kudla, D Kwekkeboom, G Rindi, G Klöppel, N Reed, R Kianmanesh, R T Jensen
No abstract text is available yet for this article.
2016: Neuroendocrinology
R Garcia-Carbonero, H Sorbye, E Baudin, E Raymond, B Wiedenmann, B Niederle, E Sedlackova, C Toumpanakis, M Anlauf, J B Cwikla, M Caplin, D O'Toole, A Perren
No abstract text is available yet for this article.
2016: Neuroendocrinology
M Pavel, D O'Toole, F Costa, J Capdevila, D Gross, R Kianmanesh, E Krenning, U Knigge, R Salazar, U-F Pape, K Öberg
No abstract text is available yet for this article.
2016: Neuroendocrinology
J K Ramage, W W De Herder, G Delle Fave, P Ferolla, D Ferone, T Ito, P Ruszniewski, A Sundin, W Weber, Z Zheng-Pei, B Taal, A Pascher
No abstract text is available yet for this article.
2016: Neuroendocrinology
U-F Pape, B Niederle, F Costa, D Gross, F Kelestimur, R Kianmanesh, U Knigge, K Öberg, M Pavel, A Perren, C Toumpanakis, J O'Connor, E Krenning, N Reed, D O'Toole
No abstract text is available yet for this article.
2016: Neuroendocrinology
Gaya Spolverato, Alessandro Vitale, Aslam Ejaz, Yuhree Kim, David Cosgrove, Todd Schlacter, Jean-Francis Geschwind, Timothy M Pawlik
BACKGROUND: Management of patients with neuroendocrine liver metastasis (NELM) remains controversial. We sought to compare the net health benefit (NHB) of hepatic resection (HR) versus intraarterial therapy (IAT) among patients with NELM. METHODS: A decision analytic Markov model was created to estimate and compare the cost effectiveness associated with different management strategies (HR vs IAT) for a simulated cohort of patients with NELM. The primary (base case) analysis was calculated based on a 57-year-old male patient with metachronous, symptomatic NELM that involved <25% of the liver in the absence of extrahepatic disease...
August 2015: Surgery
Julie Hallet, Calvin How Lim Law, Moises Cukier, Refik Saskin, Ning Liu, Simron Singh
BACKGROUND: An increased incidence of neuroendocrine tumors (NETs) has been reported worldwide, but the reasons underlying this rise have not been identified. By assessing patterns of metastatic presentation, this study sought to examine the epidemiologic characteristics of NETs and the contribution of early-stage detection to the rising incidence. METHODS: A population-based retrospective cohort study was conducted with prospectively maintained databases linked at the Institute for Clinical Evaluative Sciences...
February 15, 2015: Cancer
S Singh, J Hallet, C Rowsell, C H L Law
BACKGROUND: The Ki67-LI is a valid surrogate for biologic behavior of neuroendocrine tumors (NETs), with higher levels associated with aggressive behavior. The World Health Organization (WHO) classifies NETs according to Ki67-LI (G1: <3%; G2 : 3-20%; G3: >20%). Little is known about the evolution of NETs histologic characteristics over the disease course. We sought to evaluate variations in Ki67-LI throughout NETs disease course. METHODS: We retrospectively reviewed the Sunnybrook Odette Cancer Center NET database for patients with multiple pathology specimens...
November 2014: European Journal of Surgical Oncology
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski
BACKGROUND: Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status...
July 17, 2014: New England Journal of Medicine
Ashlie Nadler, Moises Cukier, Laurent Milot, Simron Singh, Calvin H Law
BACKGROUND: Aggressive surgical resection of neuroendocrine tumour liver metastases (NET-LM) is associated with symptomatic relief. Debulking up to 90% of tumour burden, even with positive margins, may be beneficial. However, patients with diffuse hepatic metastases may not qualify for resection owing to associated insufficient remnant liver parenchyma. The purpose of this study is to describe an early experience with a hepatic parenchymal preserving (HPP) approach. METHODS: We retrospectively reviewed our institutional neuroendocrine tumours database to identify patients with NET-LM, including symptomatic patients with extensive bilobar involvement, who underwent virtual volumetric assessment (VVA) combined with HPP resection between October 2008 and July 2011...
April 2014: Canadian Journal of Surgery. Journal Canadien de Chirurgie
Frédérique Maire, Catherine Lombard-Bohas, Dermot O'Toole, Marie-Pierre Vullierme, Vinciane Rebours, Anne Couvelard, Anne Laure Pelletier, Magaly Zappa, Frank Pilleul, Olivia Hentic, Pascal Hammel, Philippe Ruszniewski
BACKGROUND: Liver surgery is the best treatment for endocrine liver metastases, but it is often impossible due to diffuse disease. Systemic chemotherapy is poorly effective. Hepatic arterial embolization (HAE) and chemoembolization (HACE) have shown efficacy but have never been compared. PATIENTS AND METHODS: Patients with progressive unresectable liver metastases from midgut endocrine tumors were randomly assigned to receive HAE or HACE (two procedures at 3-month interval)...
2012: Neuroendocrinology
James C Yao, Manisha H Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M Wolin, Eric Van Cutsem, Timothy J Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G E de Vries, Paola Tomassetti, Marianne E Pavel, Sakina Hoosen, Tomas Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg
BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study. METHODS: We randomly assigned 410 patients who had advanced, low-grade or intermediate-grade pancreatic neuroendocrine tumors with radiologic progression within the previous 12 months to receive everolimus, at a dose of 10 mg once daily (207 patients), or placebo (203 patients), both in conjunction with best supportive care...
February 10, 2011: New England Journal of Medicine
Eric Raymond, Laetitia Dahan, Jean-Luc Raoul, Yung-Jue Bang, Ivan Borbath, Catherine Lombard-Bohas, Juan Valle, Peter Metrakos, Denis Smith, Aaron Vinik, Jen-Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui Ray Lu, Carolyn Blanckmeister, Richard Chao, Philippe Ruszniewski
BACKGROUND: The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. METHODS: We conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients with advanced, well-differentiated pancreatic neuroendocrine tumors. All patients had Response Evaluation Criteria in Solid Tumors-defined disease progression documented within 12 months before baseline...
February 10, 2011: New England Journal of Medicine
Jonathan R Strosberg, Robert L Fine, Junsung Choi, Aejaz Nasir, Domenico Coppola, Dung-Tsa Chen, James Helm, Larry Kvols
BACKGROUND: Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS). METHODS: Patients with metastatic, well, or moderately differentiated pancreatic endocrine carcinomas who had not received prior systemic chemotherapy were treated with capecitabine (750 mg/m² twice daily, days 1-14) and temozolomide (200 mg/m² once daily, days 10-14) every 28 days...
January 15, 2011: Cancer
David S Klimstra, Irvin R Modlin, Domenico Coppola, Ricardo V Lloyd, Saul Suster
Neuroendocrine tumors (NETs) arise in most organs of the body and share many common pathologic features. However, a variety of different organ-specific systems have been developed for nomenclature, grading, and staging of NETs, causing much confusion. This review examines issues in the pathologic assessment of NETs that are common among primaries of different sites. The various systems of nomenclature are compared along with new proposal for grading and staging NETs. Although differences persist, there are many common themes, such as the distinction of well-differentiated (low and intermediate-grade) from poorly differentiated (high-grade) NETs and the significance of proliferative rate in prognostic assessment...
August 2010: Pancreas
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold, Thomas Gress, Rudolf Arnold
PURPOSE: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival. PATIENTS AND METHODS: Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death...
October 1, 2009: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
A Frilling, J Li, E Malamutmann, K-W Schmid, A Bockisch, C E Broelsch
BACKGROUND: Hepatic surgery is presumed to improve survival of patients with liver metastases (LM) from neuroendocrine tumours (NET). This study identified LM-specific variables that could be used as additional selection criteria for aggressive treatment. METHODS: A novel classification of LM from NET was established based on their localization and presentation. RESULTS: From 1992 to 2006, 119 patients underwent staging and treatment of LM...
February 2009: British Journal of Surgery
Göran Akerström, Per Hellman
Neuroendocrine tumours of the gastrointestinal tract and pancreas present a major challenge to physicians in their recognition and treatment requirements, and surgical treatment of these tumours has become increasingly important for symptom palliation and survival. For some carcinoid tumours the extent of surgery may depend on tumour size. Midgut carcinoid is the most common cause of the carcinoid syndrome, requiring surgery for primary and mesenteric tumours to minimize the risk for abdominal complications but also for removal of liver metastases to palliate hormonal symptoms...
March 2007: Best Practice & Research. Clinical Endocrinology & Metabolism
2016-09-22 22:31:47
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"